Braveheart Bio, Inc. BRVE
20.90 USD +1.28 (+6.52%)
At closeNov 11, 2026, 4:26 PM EST
20.90 0.00 0.00%
After hours · Nov 11, 4:26 PM ET
19.41 Day range 21.85
16.70 52-week range 32.00
- YTD
- -29.87%
- 1 year
- -29.87%
News
globenewswire.com Braveheart Bio Reports Third Quarter 2026 Financial Results and Provides Business Update 52-week data presented at AHA Scientific Sessions 2026 further strengthen BHB-1893's potential differentiation, with encouraging clinical activity and support for a highly simplified dosing regimen…
globenewswire.com Braveheart Bio to Participate in the Jefferies Global Healthcare Conference in London SAN FRANCISCO, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic…
seekingalpha.com Braveheart Bio, Inc. (BRVE) Shareholder/Analyst Call Transcript Braveheart Bio, Inc. (BRVE) Shareholder/Analyst Call Transcript
marketbeat.com Braveheart Bio Shares One-Year Heart Drug Data, Plans New Fixed-Dose Trial Braveheart Bio NASDAQ: BRVE presented one-year data from a small study of its experimental heart drug BHB-1893 and outlined plans for a fixed-dose trial, as the company advances the treatment through…
benzinga.com Hengrui Pharma And Braveheart Bio Report Durable 52-Week HRS/BHB-1893 Benefits In oHCM; Says Data Across Both Forms Of HCM And Preclinical Models Suggest Potential To Address Underlying Pathophysiology Of Disease, Findings Consistent With Reverse-remodeling And Diastolic Benefits; To Host Investor Event And Webcast Today At 4:35 p.m. ET HRS/BHB-1893 demonstrated meaningful improvements in exercise capacity and patient-reported outcomes, with rapid, deep, and durable left ventricular outflow tract (LVOT) gradient reduction at 52…
globenewswire.com Hengrui Pharma and Braveheart Bio Present Data from 52-Week Open-Label Extension of Phase 2 Study of HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy at American Heart Association Scientific Sessions 2026 HRS/BHB-1893 demonstrated meaningful improvements in exercise capacity and patient-reported outcomes, with rapid, deep, and durable left ventricular outflow tract (LVOT) gradient reduction at 52 weeks
benzinga.com Braveheart Bio Announces Late-breaking Presentation Of 52-Week Extension Data For BHB-1893 In Obstructive HCM At The American Heart Association Scientific Sessions, November 6-9; Will Also Host Webinar Oral Abstract PresentationTitle: HRS/BHB-1893, a Next-Generation Cardiac Myosin Inhibitor, Improves Indices of Diastolic Function in Non-Obstructive Hypertrophic Cardiomyopathy: Evidence From in…
globenewswire.com Braveheart Bio Announces Upcoming Presentations at the American Heart Association Scientific Sessions 2026 SAN FRANCISCO, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic…
globenewswire.com Braveheart Bio to Host Webinar – HCM Spotlight: Advancing a Next-Generation Cardiac Myosin Inhibitor – with Key Opinion Leader Discussion on November 6, 2026 SAN FRANCISCO, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic…
seekingalpha.com Braveheart Bio: In Non-Obstructive HCM, The Therapeutic Window Is The Product Braveheart Bio is undervalued as a late-stage HCM player, with two Phase 3 programs fully funded and a differentiated molecule for non-obstructive HCM. BRVE holds $527M in pro forma cash, supporting…- benzinga.com Cantor Fitzgerald Reiterates Overweight on Braveheart Bio, Maintains $40 Price Target Cantor Fitzgerald analyst Olivia Brayer Saunders reiterates Braveheart Bio (NASDAQ:BRVE) with a Overweight and maintains $40 price target.
defenseworld.net Braveheart Bio (NASDAQ:BRVE) Stock Falls 7.3% – Here’s What Happened Shares of Braveheart Bio, Inc. (NASDAQ: BRVE - Get Free Report) were down 7.3% during mid-day trading on Wednesday. The stock traded as low as $20.86 and last traded at $20.7090. 36,478 shares were…
globenewswire.com Braveheart Bio to Participate in Stifel Cardiometabolic Forum SAN FRANCISCO, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic…- benzinga.com Braveheart Bio Q2 EPS $(2.51) Braveheart Bio (NASDAQ:BRVE) reported quarterly losses of $(2.51) per share which missed the analyst consensus estimate of $0.74 by 439.19 percent. This is a 1692.86 percent decrease over losses of…
globenewswire.com Braveheart Bio Reports Second Quarter 2026 Financial Results and Provides Business Update Phase 3 LIONHEART-HCM Trial of BHB-1893 in Obstructive Hypertrophic Cardiomyopathy (oHCM) Initiated Cash and Cash Equivalents of $122.8 Million as of June 30, 2026, or $527.3 Million After Giving…
globenewswire.com Braveheart Bio to Participate in Cantor Global Healthcare Conference SAN FRANCISCO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic…
benzinga.com This Airbnb Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings…
benzinga.com Goldman Sachs Initiates Coverage On Braveheart Bio with Buy Rating, Announces Price Target of $48 Goldman Sachs analyst Salveen Richter initiates coverage on Braveheart Bio (NASDAQ:BRVE) with a Buy rating and announces Price Target of $48.
benzinga.com This Lumentum Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings…- benzinga.com Cantor Fitzgerald Initiates Coverage On Braveheart Bio with Overweight Rating, Announces Price Target of $40 Cantor Fitzgerald analyst Olivia Brayer Saunders initiates coverage on Braveheart Bio (NASDAQ:BRVE) with a Overweight rating and announces Price Target of $40.
benzinga.com Stifel Initiates Coverage On Braveheart Bio with Buy Rating, Announces Price Target of $45 Stifel analyst James Condulis initiates coverage on Braveheart Bio (NASDAQ:BRVE) with a Buy rating and announces Price Target of $45.
fool.com Braveheart Bio CFO Acquires 27,777 Shares for $500,000. Is This a Signal BRVE IPO Is a Success? The transaction involved 27,777 shares acquired for ~$500,000 on August 7, 2026. The acquisition increased the total equity position by 5%, resulting in a 0.87% ownership stake.
fool.com Braveheart Bio Chairman Chris Viehbacher Buys $1.5M Shares at IPO. What Does This Mean for Investors? The transaction involved 83,333 shares with an estimated value of ~$1.5 million as of the August 7, 2026 market close. Director Viehbacher increased his direct equity holdings by 16% through this…
fool.com Braveheart Bio CEO Travis Murdoch Buys 83,333 Shares for $1.5 Million. Is This a Buy Signal for Investors? Murdoch exercised options at $18 per share, increasing his total beneficial ownership to ~8 million shares valued at $161 million, representing a 13% stake.
defenseworld.net Braveheart Bio (NASDAQ:BRVE) Director Purchases $999,990.00 in Stock Braveheart Bio, Inc. (NASDAQ: BRVE - Get Free Report) Director David Charles Lubner purchased 55,555 shares of the stock in a transaction dated Friday, August 7th. The shares were acquired at an…
defenseworld.net Braveheart Bio (NASDAQ:BRVE) CFO Buys $499,986.00 in Stock Braveheart Bio, Inc. (NASDAQ: BRVE - Get Free Report) CFO James Paul Rickey bought 27,777 shares of the company's stock in a transaction on Friday, August 7th. The stock was purchased at an average…
globenewswire.com Braveheart Bio Announces Closing of Upsized Initial Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares SAN FRANCISCO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic…
globenewswire.com Braveheart Bio Announces Pricing of Upsized Initial Public Offering SAN FRANCISCO, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic…
seekingalpha.com Braveheart Bio Readies $300 Million IPO Plan Braveheart Bio is targeting a $300 million IPO to advance BHB-1893, a promising HCM treatment. BRVE's candidate showed an 86% complete response rate in Phase 2 Chinese trials; Phase 3 trials are…